{"nctId":"NCT01153347","briefTitle":"A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","startDateStruct":{"date":"2010-06"},"conditions":["Major Depressive Disorder","Depression"],"count":2409,"armGroups":[{"label":"SSRI/Serotonin/SNRI+ TC-5214 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TC-5214"]},{"label":"SSRI/Serotonin/SNRI + TC-5214 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TC-5214"]},{"label":"SSRI/Serotonin/SNRI + TC-5214 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: TC-5214"]},{"label":"SSRI/Serotonin/SNRI + Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TC-5214","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of signed and dated informed consent before initiation of any study-related procedures.\n* The patient must have a clinical diagnosis of major depressive disorder (MDD) with inadequate response to no more than one antidepressant.\n* Outpatient status at enrollment and randomization.\n\nExclusion Criteria:\n\n* Patients with a lifetime history of bipolar disorder, psychotic disorder or post-traumatic stress disorder.\n* Patients with a history of suicide attempts in the past year and/or seen by the investigator as having a significant history of risk of suicide or homicide.\n* History of renal insufficiency or impairment or conditions that could affect absorption or metabolism of investigational product.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.","description":"A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"0.81"},{"groupId":"OG001","value":"-11.8","spread":"0.83"},{"groupId":"OG002","value":"-11.3","spread":"0.84"},{"groupId":"OG003","value":"-11.2","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)","description":"The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score at end of treatment (Week 16) was calculated.\n\nA 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"39.7","spread":null},{"groupId":"OG002","value":"38.8","spread":null},{"groupId":"OG003","value":"42.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)","description":"The percentage of patients with a MADRS total score of ≤8 at end of treatment (Week 16) was calculated.\n\nA 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null},{"groupId":"OG001","value":"26.9","spread":null},{"groupId":"OG002","value":"23.7","spread":null},{"groupId":"OG003","value":"29.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)","description":"The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score and a MADRS total score of ≤12 at Week 10, Week 12, Week 14, and end of treatment (Week 16) was calculated.\n\nA 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null},{"groupId":"OG001","value":"7.8","spread":null},{"groupId":"OG002","value":"8.3","spread":null},{"groupId":"OG003","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)","description":"The percentage of patients with a ≥50% reduction from randomization (Week 8) in MADRS total score and a MADRS total score of ≤12 at Week 12, Week 14, and end of treatment (Week 16) was calculated.\n\nA 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"18.7","spread":null},{"groupId":"OG002","value":"14.0","spread":null},{"groupId":"OG003","value":"15.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)","description":"The percentage of patients with a MADRS total score of ≤8 at Week 12, Week 14, and end of treatment (Week 16)was calculated.\n\nA 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":null},{"groupId":"OG001","value":"12.7","spread":null},{"groupId":"OG002","value":"7.6","spread":null},{"groupId":"OG003","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score","description":"A 17-item, clinician-rated scale that assesses depressive symptoms. The HAMD-17 consists of 17 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-17 total score is calculated as the sum of the 17 individual symptom scores; the total score can range from 0 to 52. Higher HAMD-17 scores indicate more severe depression.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"0.79"},{"groupId":"OG001","value":"-9.7","spread":"0.79"},{"groupId":"OG002","value":"-9.5","spread":"0.79"},{"groupId":"OG003","value":"-9.1","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)","description":"A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline). Each item is scored on a 1 to 7 scale. Higher CGI-S scores indicate greater illness severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.10"},{"groupId":"OG001","value":"-1.3","spread":"0.11"},{"groupId":"OG002","value":"-1.2","spread":"0.11"},{"groupId":"OG003","value":"-1.2","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of \"Very Much Improved\" or \"Much Improved\" From Randomization (Week 8) to End of Treatment (Week 16)","description":"A 3-part, clinician-administered scale that rates the improvement or worsening of the patient's illness from randomization (baseline). Each item is scored on a 1 to 7 scale. CGI-I scores \\>4 indicate worsening, while scores \\<4 indicate improvement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.4","spread":null},{"groupId":"OG001","value":"49.4","spread":null},{"groupId":"OG002","value":"37.5","spread":null},{"groupId":"OG003","value":"47.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Anxiety Scale (HAM-A) Total Score From Randomization (Week 8) to End of Treatment (Week 16)","description":"A 14-item clinician-administered scale for the evaluation of anxiety symptoms. Each HAM-A item is rated on a 0 to 4 scale, the total score can range from 0 to 56. Higher HAM-A scores indicate higher levels of anxiety.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.07","spread":"0.648"},{"groupId":"OG001","value":"-6.46","spread":"0.652"},{"groupId":"OG002","value":"-6.75","spread":"0.655"},{"groupId":"OG003","value":"-6.24","spread":"0.641"}]}]}]},{"type":"SECONDARY","title":"Change in MADRS Total Score From Randomization (Week 8) to Week 9","description":"A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"0.52"},{"groupId":"OG001","value":"-5.1","spread":"0.52"},{"groupId":"OG002","value":"-4.0","spread":"0.52"},{"groupId":"OG003","value":"-5.0","spread":"0.52"}]}]}]},{"type":"SECONDARY","title":"Change in MADRS Total Score From Randomization (Week 8) to Week 10","description":"A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.3","spread":"0.60"},{"groupId":"OG001","value":"-6.9","spread":"0.60"},{"groupId":"OG002","value":"-7.3","spread":"0.61"},{"groupId":"OG003","value":"-7.1","spread":"0.60"}]}]}]},{"type":"SECONDARY","title":"Change in MADRS Total Score From Randomization (Week 8) to Week 12","description":"A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"0.70"},{"groupId":"OG001","value":"-9.4","spread":"0.71"},{"groupId":"OG002","value":"-8.9","spread":"0.73"},{"groupId":"OG003","value":"-8.5","spread":"0.70"}]}]}]},{"type":"SECONDARY","title":"Change in MADRS Total Score From Randomization (Week 8) to Week 14","description":"A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0","spread":"0.74"},{"groupId":"OG001","value":"-11.3","spread":"0.76"},{"groupId":"OG002","value":"-10.6","spread":"0.77"},{"groupId":"OG003","value":"-10.7","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score","description":"Sheehan Disability Scale (SDS) is 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The SDS total score is calculated as the sum of the score for the 3 inter-correlated domains (school/work, social life, and family life/home responsibilities) and ranges from 0 (unimpaired) to 30 (highly impaired).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.53","spread":"0.631"},{"groupId":"OG001","value":"-5.45","spread":"0.643"},{"groupId":"OG002","value":"-4.53","spread":"0.651"},{"groupId":"OG003","value":"-4.93","spread":"0.627"}]}]}]},{"type":"SECONDARY","title":"Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score","description":"A 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities. The numerical rating for the work/school domain score is 0- 10, where 10 is considered to be 'highly impaired'.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.21"},{"groupId":"OG001","value":"-1.8","spread":"0.22"},{"groupId":"OG002","value":"-1.7","spread":"0.21"},{"groupId":"OG003","value":"-1.7","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score","description":"A 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities. The numerical rating for the SDS social life domain score is 0- 10, where 10 is considered to be 'highly impaired'.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.22"},{"groupId":"OG001","value":"-1.9","spread":"0.23"},{"groupId":"OG002","value":"-1.6","spread":"0.23"},{"groupId":"OG003","value":"-1.9","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score","description":"A 5-item, self-administered scale that measures the extent a patient is impaired by their disease. Higher scores indicate more severe impairment. The 3 inter-correlated domains are school/work, social life, and family life/home responsibilities. The numerical rating for the SDS family life/home responsibilities domain score is 0- 10, where 10 is considered to be 'highly impaired'.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"0.22"},{"groupId":"OG001","value":"-1.8","spread":"0.23"},{"groupId":"OG002","value":"-1.6","spread":"0.23"},{"groupId":"OG003","value":"-1.6","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score","description":"The Q-LES-Q-SF total score is derived by summing item scores 1 to 14. Higher scores are indicative of greater enjoyment or satisfaction in each domain. The Q-LES-Q-SF % maximum total score is calculated as 100% × (Q-LES-Q-SF total score - 14) / 56, and can range from 0% to 100%.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.81","spread":"1.470"},{"groupId":"OG001","value":"11.42","spread":"1.483"},{"groupId":"OG002","value":"8.83","spread":"1.499"},{"groupId":"OG003","value":"10.71","spread":"1.467"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form(Q LES-Q-SF)Item 15","description":"The Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) measures the patient's satisfaction with medication and overall quality of life. The 15th item queries respondents' satisfaction with the medication they are taking, rated on a 1 to 4 scale, score 0 indicates that no medication was taken. Higher scores are indicative of greater satisfaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.08"},{"groupId":"OG001","value":"0.4","spread":"0.08"},{"groupId":"OG002","value":"0.2","spread":"0.08"},{"groupId":"OG003","value":"0.4","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16","description":"The Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form) measures the patient's satisfaction with medication and overall quality of life. The 16th item is a global rating of overall life satisfaction and contentment, rated on a 1 to 5 scale. Higher scores are indicative of greater satisfaction.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.08"},{"groupId":"OG001","value":"0.5","spread":"0.08"},{"groupId":"OG002","value":"0.4","spread":"0.08"},{"groupId":"OG003","value":"0.5","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","description":"A self-assessment questionnaire that provides 2 measures of health status. The EQ-5D index score is a weighted linear combination over 5 dimensions of health status. The score for each of the 5 dimensions can range from 1 to 3, and an equation is used to calculate the EQ-5D index score. The EQ-5D index score can range from possible negative values (minimum -0.415) to a maximum of 1.0. The EQ-VAS is a visual analog scale with a range of 0 to 100. For both variables, a higher score indicates a better health state.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.114","spread":"0.0169"},{"groupId":"OG001","value":"0.107","spread":"0.0173"},{"groupId":"OG002","value":"0.106","spread":"0.0176"},{"groupId":"OG003","value":"0.120","spread":"0.0168"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":"1.69"},{"groupId":"OG001","value":"12.9","spread":"1.73"},{"groupId":"OG002","value":"10.3","spread":"1.76"},{"groupId":"OG003","value":"11.5","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)","description":"A self-administered scale to be used by clinical subjects to rate suffering over the past week with regard to irritability symptoms. The total SIS score is the sum of 7 items, and ranges from 0 to 70. Each item is assessed on an 11- point scale where 0=not at all, 1-3=mildly, 4-6=moderately, 7-9=markedly, and 10=extremely. The SIS also records the number of days impaired by irritability.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.2","spread":"1.46"},{"groupId":"OG001","value":"-10.1","spread":"1.49"},{"groupId":"OG002","value":"-8.3","spread":"1.50"},{"groupId":"OG003","value":"-8.8","spread":"1.46"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":160},"commonTop":["Constipation","Headache","Nausea","Diarrhoea","Dizziness"]}}}